← ARS Pharmaceuticals, Inc. (SPRY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ARS Pharmaceuticals, Inc. (SPRY)
Pharmaceutical Preparations · market cap $422M · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
ARS Pharmaceuticals (SPRY) is a ~$695M market-cap specialty pharma with 162 employees, anchored by two Phase 2 assets: ARS-1 for asthma and a 0.5 mg epinephrine formulation for chronic urticaria. The company generated $84M in revenue in 2025 but posted a net loss of $171M and holds only $24.3M in cash against $72.2M in net debt, implying roughly 1.6 months of runway — a severe near-term financing overhang.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ARS-1 | Phase 2 | Asthma |
| 0.5 mg epinephrine | Phase 2 | Urticaria Chronic |
Price & technical context
3-month
-51.9%
6-month
-49.2%
12-month
-59.0%
52-wk range
$4.08–$13.06
vs 50-day MA
-22.3%
vs 200-day MA
-49.4%
Realized vol
74.7%
Max drawdown
-77.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SPRY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.